ContactDictionary

Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  ado trastuzumab emtansine
Find trials that include:  Any drugs shown
Results 1-12 of 12 for your search:
Start Over
A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NSABP FB-10, NCI-2015-00275, NCT02236000
Ribociclib with Trastuzumab or Trastuzumab Emtansine in Treating Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Tissue collection/Repository
Age: 18 and over
Trial IDs: 15-530, NCI-2016-00505, NCT02657343
Trastuzumab Emtansine with or without Temozolomide in Preventing Development of Brain Metastases after Stereotactic Radiosurgery in Patients with HER2 Positive Brea t Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 17-C-0115, NCI-2017-01113, NCT03190967
Trastuzumab Emtansine and Pertuzumab before Surgery in Treating Patients with HER2-Positive Stage II-III Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-409, NCI-2015-00454, NCT02326974
Trastuzumab Emtansine in Treating Older Patients with Human Epidermal Growth Factor Receptor 2-Positive Stage I-III Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 65 and over
Trial IDs: RU011301I, NCI-2015-00468, NCT02414646
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EAY131, NCI-2015-00054, NCT02465060
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TDM4529g, NCI-2009-01154, 2010-021067-32, BO25430, NCT00781612
Trastuzumab Emtansine in Treating Patients with HER2 Amplified or Mutant Advanced Cancers
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-335, NCI-2016-00262, NCT02675829
Palbociclib Isethionate and Ado-Trastuzumab Emtansine in Treating Patients with Recurrent or Metastatic HER2-Positive Breast Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 to 90
Trial IDs: SCCC-05113, NCI-2014-00821, 042013-042, 8843, Mod13_STU 042013-042, Mod9_STU 042013-042, NCT01976169
Taselisib and Anti-HER2 Therapy in Treating Patients with Advanced HER2+ Breast Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 15-024, NCI-2015-00627, ML29407, NCT02390427
Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29831, NCI-2015-02225, 2015-002113-29, NCT02605915
Pembrolizumab and Trastuzumab Emtansine in Treating Patients with Metastatic HER2-Positive Breast Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 16-492, NCI-2017-00402, NCT03032107
Start Over